托特罗定联合黛力新治疗女性膀胱过度活动症的临床应用  

Treatment effect of Flupentixol combined with Melitracen for overactive bladder in female population

作　　者：白肃[1] 蒙巍[1] 麻日虎[1] 罗宝华[1] 赖萍新[1] 

机构地区：[1]深圳市龙岗区人民医院泌尿外科,广东深圳518172

出　　处：《中国现代医生》2012年第17期76-77,79,共3页China Modern Doctor

摘　　要：目的比较托特罗定联合黛力新与单用托特罗定治疗女性膀胱过度活动症的疗效。方法将120例女性膀胱过度活动症患者随机分为托特罗定联合黛力新治疗组60例与单用托特罗定治疗组60例,治疗时间为4周,以平均24 h排尿次数、最大尿流率(Qmax)、残余尿量为疗效指标,比较两组疗效。结果两组比较治疗前后24 h排尿次数、最大尿流率(Qmax)、残余尿量,差异有统计学意义(P<0.05),联合用药组上述指标的改善程度明显优于单用组。结论托特罗定联合黛力新治疗女性膀胱过度活动症的疗效优于单用托特罗定。Objective Comparing the clinical effect of Toherodine combined with Flupeutixol and Melitracen and that of Toherodine alone for female overactive bladder （OAB）. Methods A total of 120 female patients with OAB were randomly divided into Toherodine plus Flupentixol and Melitracen treatment group A （group A, n = 60） and Tolterodine alone treat- ment group （group B, n = 60）. The effects were evaluated wit hurodynamic data including frequency of mict uriation and uncontinence, maximum flow rate （Qmax） ,maximum cystometric capacity （MCC） and first desire to void. Results The changes of frequency of mict uriation and uncontinence, Qmax, FDV, and MCC had significant difference between the two groups （P 〈 0.05）. Respectively, all the urodynamic data of group A showed significant improvement, compared with those of group B. Conclusion Tolterodine combined with Flupentixol and Melitracen could be an effective method for female overactive bladder.

关 键 词：膀胱过度活动症 托特罗定 黛力新 药物治疗 

分 类 号：R694[医药卫生—泌尿科学]